Talecris Biotherapeutics acquired the contributed assets of the worldwide plasma business of Bayer Biological Products and became operational April 1, 2005. All plasma-based products - including Gamunex, Prolastin, the hyperimmune line (Fraction II), Plasbumin (Bayer Albumin), Koate DVI and Thrombate III - related facilities, and employees are now functioning under the name Talecris Biotherapeutics.

Bayer HealthCare will continue to support the hemophilia community by the manufacturing and selling of Kogenate® FS. Bayer HealthCare is intent on focusing additional resources on Kogenate FS to grow its market position and strengthen its leadership profile, continuing its more than 30 year tradition of driving progress in hemophilia care.